CG Oncology, Inc. Operating Lease, Weighted Average Discount Rate, Percent
CG Oncology, Inc. (CGON) had Operating Lease, Weighted Average Discount Rate, Percent of 6.90% as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Leases
us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent · last filed 2026-08-06
- 2026-06-30: Operating Lease, Weighted Average Discount Rate, Percent 6.90%.
- 2026-03-31: Operating Lease, Weighted Average Discount Rate, Percent 6.90%.
- 2025-12-31: Operating Lease, Weighted Average Discount Rate, Percent 6.89%.
- 2025-09-30: Operating Lease, Weighted Average Discount Rate, Percent 6.87%.
| Period end | Operating Lease, Weighted Average Discount Rate, Percent |
|---|---|
| 2026-06-30 | 6.90% 10-Q · filed 2026-08-06 |
| 2026-03-31 | 6.90% 10-Q · filed 2026-05-08 |
| 2025-12-31 | 6.89% 10-K · filed 2026-02-27 |
| 2025-09-30 | 6.87% 10-Q · filed 2025-11-14 |
| 2025-06-30 | 6.85% 10-Q · filed 2026-08-06 |
| 2025-03-31 | 6.77% 10-Q · filed 2026-05-08 |
| 2024-12-31 | 1.63% 10-K · filed 2026-02-27 |
| 2024-09-30 | 1.63% 10-Q · filed 2025-11-14 |
| 2024-06-30 | 1.63% 10-Q · filed 2025-08-08 |
| 2024-03-31 | 1.63% 10-Q · filed 2025-05-13 |
| 2023-12-31 | 1.63% 10-K · filed 2025-03-28 |
| 2023-09-30 | 1.63% 10-Q · filed 2024-11-12 |
| 2023-06-30 | 1.63% 10-Q · filed 2024-08-08 |
| 2023-03-31 | 1.63% 10-Q · filed 2024-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |